|
|
|
Douglas
Anderson
|
 |
| Douglas
Anderson's research program is focused on understanding the mechanisms
responsible for tissue damage following spinal cord injury (SCI) and
then testing appropriate therapeutic interventions including pharmacological
agents, neural tissue transplantation, gene delivery, and directed
rehabilitative strategies to reduce the effects of acute SCI. |
 |
Professor
of Neuroscience
Chairman, Neuroscience Department
Investigator, McKnight Brain Institute
Training
Postdoc - National Research Council Research Associate, U.S.
Air Force School of Aerospace Medicine, Brooks Air Force Base,
Texas
Ph.D. Physiology, Michigan State University, East Lansing, Michigan
M.Sc. Biology, University of Houston, Houston, Texas
B.S. Zoology, University of Texas, Austin, Texas
|
Contact
phone:
352.392.6641
office: MBI L1-100H
lab: MBI L2-135
email:anderson@mbi.ufl.edu
|
|
| Repair
of the injured spinal cord (SCI) has been the subject of my
research program for 30 years. Initially, we focused on identifying
the pathophysiological events involved in the secondary injury
process and developing acute pharmacotherapy for SCI. These
studies contributed to the use of methylprednisolone (MP) for
the treatment of acute SCI in humans. We are continuing studies
of the acute injury by evaluating changes in gene expression
induced by acute SCI in a well-established rat model. These
genes play protective and damaging roles in the acute injury
site. The ultimate goal of these studies is to develop therapeutic
regimens such as gene therapy to upregulate those genes which
have been determined to be beneficial following SCI. A second
focus in my laboratory is aimed toward the development of strategies
to repair the chronically injured spinal cord. Our recent neural
tissue transplant studies were the basis for a clinical pilot
study to test the feasibility and safety of neural tissue transplants
in patients with progressive syringomyelia, a severe, chronic
complication of SCI. |
Recent
Publications
Cellular
localization and enzymatic activity of cathepsin B after spinal
cord injury in the rat . Ellis RC, O’Steen WA, Hayes
RL , Nick HS, Wang KKW, Anderson DK. Exp. Neurology 193(1):19-28,
2005.
Recommended guidelines for studies of human subjects with spinal
cord injury. Anderson DK, Beattie M, Blesch A, Bresnahan
J, Bunge M, Dietrich D, Dietz V, Dobkin B, Fawcett J, Fehlings
M, Fischer I, Grossman R, Guest J, Hagg T, Hall ED, Houle J,
Kleitman N, McDonald J, Murray M, Privat A, Reier P, Steeves
J, Steward O, Tetzlaff W, Tuszynski MH, Waxman SG, Whittemore
S, Wolpaw J, Young W, Zheng B. Spinal Cord, 12 April
2005.
Intact aggrecan and chondroitin sulfate-depleted aggrecan
core glycoprotein inhibit axon growth in the adult rat spinal
cord. Lemons ML, Sandy JD, Anderson DK, Howland DR. Exp
Neurol. 184/2:981-990, 2003.
|
|
|
